{"id":"agalsidase","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Infusion-associated reactions","drugRate":"59%","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Chills","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"","severity":"common","organSystem":""},{"effect":"Paresthesia","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Severe infusion-associated reactions","drugRate":"5%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["agalsidase beta; Fabrazyme","agalsidase alfa; Replagal"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"988513ab-b06f-4dd0-93f7-d2d4531dcce4","title":"FABRAZYME (AGALSIDASE BETA) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENZYME CORPORATION]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T01:00:17.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/%CE%91-Galactosidase","title":"Α-Galactosidase","extract":"α-Galactosidase is a glycoside hydrolase enzyme that catalyses the following reaction:Hydrolysis of terminal, non-reducing α-D-galactose residues in α-D-galactosides, including galactooligosaccharides (GOS), galactomannans and galactolipids"},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Fabry's disease","diseaseId":"fabry's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05280548","phase":"PHASE3","title":"A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-05-03","conditions":"Fabry Disease","enrollment":104},{"nctId":"NCT00196742","phase":"","title":"Fabry Disease Registry & Pregnancy Sub-registry","status":"RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-07-31","conditions":"Fabry Disease","enrollment":9000},{"nctId":"NCT05843916","phase":"PHASE3","title":"Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease","status":"COMPLETED","sponsor":"Bio Sidus SA","startDate":"2022-12-13","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT02956954","phase":"NA","title":"Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-03-25","conditions":"Anderson-Fabry Disease","enrollment":26},{"nctId":"NCT04281537","phase":"","title":"A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2020-03-01","conditions":"Fabry Disease","enrollment":82},{"nctId":"NCT07187440","phase":"","title":"A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-01","conditions":"Fabry Disease","enrollment":200},{"nctId":"NCT07235709","phase":"","title":"Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2025-11-12","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT05343715","phase":"PHASE1","title":"PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion","status":"COMPLETED","sponsor":"Bio Sidus SA","startDate":"2021-10-23","conditions":"Fabry Disease","enrollment":24},{"nctId":"NCT05067868","phase":"PHASE4","title":"A Study of Replagal in Children and Adults With Fabry Disease in India","status":"RECRUITING","sponsor":"Shire","startDate":"2022-11-01","conditions":"Fabry Disease","enrollment":5},{"nctId":"NCT05054387","phase":"PHASE4","title":"China Post-marketing Surveillance (PMS) Study of Fabrazyme®","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2021-10-13","conditions":"Fabry Disease","enrollment":22},{"nctId":"NCT06052800","phase":"","title":"Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-09-13","conditions":"Fabry Disease","enrollment":78},{"nctId":"NCT04974749","phase":"PHASE3","title":"A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-05-01","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT06081062","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease","status":"RECRUITING","sponsor":"ISU Abxis Co., Ltd.","startDate":"2023-04-14","conditions":"Fabry Disease","enrollment":24},{"nctId":"NCT04840667","phase":"PHASE3","title":"A Study of Replagal in Treatment-naïve Adults With Fabry Disease","status":"TERMINATED","sponsor":"Shire","startDate":"2021-12-28","conditions":"Fabry Disease","enrollment":17},{"nctId":"NCT00230607","phase":"PHASE4","title":"Study of the Effects of Fabrazyme Treatment on Lactation and Infants","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-05-28","conditions":"Fabry Disease, Alpha Galactosidase A Deficiency","enrollment":7},{"nctId":"NCT05698901","phase":"","title":"Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2023-09-19","conditions":"Fabry Disease","enrollment":150},{"nctId":"NCT02795676","phase":"PHASE3","title":"Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function","status":"COMPLETED","sponsor":"Protalix","startDate":"2016-06","conditions":"Fabry Disease","enrollment":78},{"nctId":"NCT03018730","phase":"PHASE3","title":"Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)","status":"COMPLETED","sponsor":"Protalix","startDate":"2017-05-17","conditions":"Fabry Disease","enrollment":22},{"nctId":"NCT04143958","phase":"PHASE4","title":"To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2020-09","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT00084084","phase":"PHASE2","title":"Replagal Enzyme Replacement Therapy for Children With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2004-06-10","conditions":"Fabry Disease","enrollment":17},{"nctId":"NCT01304277","phase":"PHASE2","title":"This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-17","conditions":"Fabry Disease","enrollment":17},{"nctId":"NCT03230591","phase":"","title":"Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-07-12","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00864851","phase":"PHASE3","title":"Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-12-29","conditions":"Fabry Disease","enrollment":44},{"nctId":"NCT01363492","phase":"PHASE2","title":"Safety Study of Replagal® Therapy in Children With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-12","conditions":"Fabry Disease","enrollment":15},{"nctId":"NCT01124643","phase":"PHASE3","title":"Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-13","conditions":"Fabry Disease","enrollment":35},{"nctId":"NCT01298141","phase":"PHASE3","title":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-10","conditions":"Fabry Disease","enrollment":171},{"nctId":"NCT01031173","phase":"","title":"Treatment Protocol of Replagal for Patients With Fabry Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Shire","startDate":"","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT01268241","phase":"","title":"The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease","status":"COMPLETED","sponsor":"CENTOGENE GmbH Rostock","startDate":"2010-12","conditions":"Fabry Disease, Fabry´s Disease, Anderson-Fabry Disease","enrollment":200},{"nctId":"NCT01196871","phase":"PHASE2","title":"Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2011-02-02","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT01218659","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2011-09-08","conditions":"Fabry Disease","enrollment":68},{"nctId":"NCT02969200","phase":"","title":"Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance","status":"COMPLETED","sponsor":"Ulla Feldt-Rasmussen","startDate":"2015-04","conditions":"Fabry Disease","enrollment":52},{"nctId":"NCT02930655","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2015-02-01","conditions":"Fabry Disease","enrollment":14},{"nctId":"NCT01745185","phase":"","title":"Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta","status":"COMPLETED","sponsor":"O & O Alpan LLC","startDate":"2012-06","conditions":"Fabry Disease","enrollment":30},{"nctId":"NCT00701415","phase":"PHASE3","title":"A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-09","conditions":"Fabry Disease","enrollment":31},{"nctId":"NCT00140621","phase":"PHASE4","title":"A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-07","conditions":"Fabry Disease","enrollment":6},{"nctId":"NCT00233870","phase":"","title":"A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-06","conditions":"Fabry Disease","enrollment":405},{"nctId":"NCT00837824","phase":"PHASE2","title":"Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-12","conditions":"Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)","enrollment":20},{"nctId":"NCT00196716","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-06","conditions":"Fabry Disease","enrollment":21},{"nctId":"NCT00074958","phase":"PHASE2","title":"A Study of Fabrazyme in Pediatric Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-10","conditions":"Fabry Disease","enrollment":16},{"nctId":"NCT00081497","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-01","conditions":"Fabry Disease","enrollment":67},{"nctId":"NCT00068107","phase":"PHASE2","title":"Dosing Study of Replagal in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2003-09","conditions":"Fabry Disease","enrollment":13},{"nctId":"NCT01997489","phase":"PHASE4","title":"Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2001-09","conditions":"Fabry Disease","enrollment":39},{"nctId":"NCT01650779","phase":"PHASE4","title":"A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2012-04","conditions":"Fabry Disease","enrollment":15},{"nctId":"NCT01632111","phase":"","title":"Pulmonary Involvement in Patients With Fabry Disease","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2012-07","conditions":"Fabry Disease","enrollment":110},{"nctId":"NCT00312767","phase":"PHASE4","title":"A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.","status":"WITHDRAWN","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-04","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT00074984","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-02","conditions":"Fabry Disease","enrollment":82},{"nctId":"NCT00074971","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"1999-10","conditions":"Fabry Disease","enrollment":58},{"nctId":"NCT00446862","phase":"","title":"The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-03","conditions":"Fabry Disease, Proteinuria","enrollment":36},{"nctId":"NCT00343577","phase":"","title":"Antiproteinuric Agents and Fabry Disease","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2001-01","conditions":"Fabry Disease, Proteinuria","enrollment":12},{"nctId":"NCT00357786","phase":"PHASE1","title":"An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10","conditions":"Fabry Disease","enrollment":3},{"nctId":"NCT00075244","phase":"PHASE2","title":"Alternative Dosing and Regimen of Replagal to Treat Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-01","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00071877","phase":"PHASE2","title":"An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00097890","phase":"PHASE4","title":"Replagal Enzyme Replacement Therapy for Adults With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-11","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00487630","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-06","conditions":"Fabry Disease","enrollment":34}],"_emaApprovals":[],"_faersSignals":[{"count":111,"reaction":"FATIGUE"},{"count":105,"reaction":"PAIN"},{"count":104,"reaction":"MALAISE"},{"count":70,"reaction":"PAIN IN EXTREMITY"},{"count":64,"reaction":"PYREXIA"},{"count":63,"reaction":"HEADACHE"},{"count":61,"reaction":"NAUSEA"},{"count":60,"reaction":"DIZZINESS"},{"count":59,"reaction":"DYSPNOEA"},{"count":58,"reaction":"VOMITING"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":499,"therapeuticAreas":["Rare Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"agalsidase","genericName":"agalsidase","companyName":"Amicus Therapeutics","companyId":"amicus-therapeutics","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}